Recent AMLX News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2024 01:12:58 PM
- Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome • Business Wire • 10/17/2024 01:00:00 PM
- Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024 • Business Wire • 10/15/2024 01:00:00 PM
- Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm • PR Newswire (US) • 10/03/2024 07:06:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/02/2024 10:53:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/02/2024 10:53:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/02/2024 10:48:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/25/2024 09:56:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 09:39:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/09/2024 08:05:06 PM
- Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences • Business Wire • 08/28/2024 12:30:00 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 08/26/2024 10:49:57 PM
- Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’s Disease Pathology and Neurodegeneration • Business Wire • 08/12/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 11:14:15 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:09:33 AM
- Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results • Business Wire • 08/08/2024 11:00:00 AM
- Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024 • Business Wire • 08/05/2024 01:00:00 PM
- Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome • Business Wire • 08/02/2024 01:00:00 PM
- Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm • PR Newswire (US) • 07/18/2024 11:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2024 11:09:00 AM
- Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation • Business Wire • 07/10/2024 11:00:00 AM
- Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide • Business Wire • 07/09/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:52:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:50:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:49:06 PM
Vocodia Enters Medical Alert Industry with Innovative Emergency Response Pendant • VHAI • Oct 25, 2024 8:00 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for Third Quarter 2024 • HYDI • Oct 24, 2024 11:18 AM
VAYK Asserts Goal of Q4 Operationally Profitable and Projects Major 2025 Launch • VAYK • Oct 24, 2024 10:40 AM
CBD Life Sciences Inc. (CBDL) Positioned for Significant Growth Amid Nationwide Marijuana Legalization Push • CBDL • Oct 24, 2024 7:07 AM
ZenaTech, Inc. (NASDAQ: ZENA) Software Company Acquisition • AVXL • Oct 23, 2024 8:03 AM
Forte Minerals to Acquire the Miscanthus Epithermal Gold and Porphyry Copper Prospects in Central Perú with Environmental Drilling Permit (DIA) • CUAU • Oct 23, 2024 7:38 AM